Schering-Plough's Claritin-D
This article was originally published in The Tan Sheet
Executive Summary
FDA approves Rx antihistamine/decongestant combination product on Nov. 14 after a six-and-one-half year review at the agency. The loratadine 5 mg/pseudoephedrine 120 mg combination is approved for twice-daily dosing. Schering-Plough is developing a one-a-day version of the low-sedating antihistamine